Study Results Presented at the 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance with Biocept's ctDNA Liquid Biopsy Platform vs. Tissue Biopsy
"In this dataset,
In the study, analysis with
"These study results validate the ability of our Target Selector™ tests to comprehensively profile a patient's cancer, and further demonstrate the high sensitivity and specificity of our dual ctDNA and CTC assay platforms," said
"We are pleased that these findings, generated by world-class collaborators from both academia and biopharma, were presented at the Annual
Physicians interested in ordering
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, our liquid biopsy platform being a
viable noninvasive alternative for establishing mutational status and for identifying secondary resistance mutations, our liquid biopsy platform being capable of proving real-time monitoring of patients' clinical status, and our ability to increase physician adoption of our technology, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-results-presented-at-the-2016-esmo-annual-congress-demonstrate-leading-clinical-performance-with-biocepts-ctdna-liquid-biopsy-platform-vs-tissue-biopsy-300348226.html
SOURCE
News Provided by Acquire Media